Literature DB >> 19028781

Incidence, clinical characteristics, and long-term prognosis of travel-associated pulmonary embolism.

Ralf Lehmann1, Christian Suess, Maria Leus, Beate Luxembourg, Wolfgang Miesbach, Edelgard Lindhoff-Last, Andreas M Zeiher, Ioakim Spyridopoulos.   

Abstract

AIMS: Prolonged air travel is considered a risk factor for pulmonary embolism (PE). The clinical characteristics as well as the long-term prognosis of patients suffering from travel-associated PE ('economy-class syndrome', ECS) remain largely unknown. Owing to its proximity, our hospital is the primary referral centre for Frankfurt Airport, Europe's third-largest airport. The goal of our study was to follow-up all patients with ECS, who were admitted to our hospital between 1997 and 2006. METHODS AND
RESULTS: We systematically reviewed all medical charts from patients presenting with acute PE to our emergency room or intensive care unit (ICU) and performed a telephone follow-up on patients discharged alive. Together with the data provided from the statistics department of Fraport Inc., the operating company of the Frankfurt International Airport, we were also able to put the medical data in context with the corresponding number of passengers and flight distances. A total of 257 patients with acute PE were admitted to our emergency and ICU between 1997 and 2006. Out of these, 62 patients suffered from ECS (45 flight-associated PE and 17 from other travel-associated PE). ECS patients were prone to more haemodynamic relevant acute events, reflected by a higher rate of initial cardiopulmonary resuscitation (4.8% vs. 1.5%; P = 0.153) and higher percentage of massive PE (8% vs. 3%; P = 0.064). Nevertheless, intrahospital mortality was similar in both groups (ECS 4.8%, others 4.1%; P = 0.730). Interestingly, the long-term outcome of ECS patients was excellent (Kaplan-Meier analysis; P log-rank: 0.008 vs. other entities). In general, ECS was a rare event (one event/5 million passengers), where long-haul flights over 5000 km lead to a 17-fold risk increase compared with shorter flights.
CONCLUSIONS: Travel-associated PE was a common cause of PE in our hospital, with patients showing excellent long-term prognosis after discharge. The risk of ECS is rather low and strictly dependent on the flight distance.

Entities:  

Mesh:

Year:  2008        PMID: 19028781     DOI: 10.1093/eurheartj/ehn500

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  6 in total

1.  EANM guidelines for ventilation/perfusion scintigraphy : Part 1. Pulmonary imaging with ventilation/perfusion single photon emission tomography.

Authors:  M Bajc; J B Neilly; M Miniati; C Schuemichen; M Meignan; B Jonson
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-08       Impact factor: 9.236

2.  Importance of risk factors for the evaluation of patients with a suspected pulmonary embolism.

Authors:  Joachim Gruettner; Tim Viergutz; Merle Bolte; Thomas Henzler; Stefan O Schoenberg; Sonja Sudarski; Paul Apfaltrer; Thomas Walter
Journal:  Exp Ther Med       Date:  2015-03-30       Impact factor: 2.447

Review 3.  In-flight medical emergencies.

Authors:  Jürgen Graf; Uwe Stüben; Stefan Pump
Journal:  Dtsch Arztebl Int       Date:  2012-09-14       Impact factor: 5.594

4.  Travel-Associated Venous Thromboembolism.

Authors:  Isla McKerrow Johnson; Joseph Shatzel; Sven Olson; Tovah Kohl; Andrew Hamilton; Thomas G DeLoughery
Journal:  Wilderness Environ Med       Date:  2022-03-31       Impact factor: 1.479

5.  Bilateral Pulmonary Embolism after a Short-Haul Flight in a Man with Multiple Risk Factors including Sickle Cell Trait.

Authors:  Kamille Abdool; Kanterpersad Ramcharan; Antonio J Reyes; Nadiene Lutchman; Adrian Alexander
Journal:  Case Rep Emerg Med       Date:  2017-03-29

6.  Detection of Pulmonary Embolism in Returning Travelers with Hypoxemic Pneumonia due to COVID-19 in Reunion Island.

Authors:  Kevin Larsen; Nathalie Coolen-Allou; Laurie Masse; Alexandre Angelino; Jérôme Allyn; Lea Bruneau; Adrien Maillot; Marie Lagrange-Xelot; Thierry Vitry; Michel André; Jean Yves Travers; Emilie Foch; Nicolas Allou
Journal:  Am J Trop Med Hyg       Date:  2020-07-01       Impact factor: 2.345

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.